

Dolores Isla

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3584578/dolores-isla-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

123
papers

12,923
citations

35
h-index

113
g-index

133
ext. papers

14,581
ext. citations

5.7
avg, IF

4.92
L-index

#	Paper	IF	Citations
123	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2012 , 13, 239-46	21.7	3985
122	Screening for epidermal growth factor receptor mutations in lung cancer. <i>New England Journal of Medicine</i> , 2009 , 361, 958-67	59.2	1809
121	A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. <i>Nature</i> , 2008 , 452, 638-642	50.4	1239
120	Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. <i>Nature Genetics</i> , 2009 , 41, 221-7	36.3	509
119	Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2747-54	2.2	391
118	Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8636-45	2.2	339
117	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 897-907	21.7	314
116	Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. <i>Clinical Cancer Research</i> , 2004 , 10, 1318-25	12.9	313
115	Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. <i>Clinical Cancer Research</i> , 2011 , 17, 1160-8	12.9	258
114	Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. <i>European Respiratory Journal</i> , 2011 , 37, 624-31	13.6	256
113	Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2004 , 15, 1194-203	10.3	242
112	Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3138-45	2.2	228
111	Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. <i>JAMA Oncology</i> , 2015 , 1, 149-57	13.4	193
110	Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3207-13	2.2	159
109	Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 959-71	9.7	153
108	Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. <i>Annals of Oncology</i> , 2006 , 17, 1205-12	10.3	153
107	Adjuvant docetaxel for high-risk, node-negative breast cancer. <i>New England Journal of Medicine</i> , 2010 , 363, 2200-10	59.2	149

106	Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2006 , 17, 668-75	10.3	137
105	Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. <i>PLoS ONE</i> , 2009 , 4, e5133	3.7	116
104	Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. <i>Annals of Oncology</i> , 2006 , 17, 467-72	10.3	106
103	Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. <i>European Journal of Cancer</i> , 2012 , 48, 1957-68	7.5	98
102	Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. <i>Clinical Cancer Research</i> , 2019 , 25, 64-72	12.9	96
101	Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4736-42	2.2	87
100	Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. <i>Clinical Cancer Research</i> , 2006 , 12, 7222-31	12.9	75
99	CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. <i>European Journal of Cancer</i> , 2020 , 127, 160-172	7.5	69
98	Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. <i>Journal of Translational Medicine</i> , 2010 , 8, 135	8.5	68
97	Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. <i>Annals of Oncology</i> , 2012 , 23, 1111-1120	10.3	66
96	Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. <i>Lung Cancer</i> , 2014 , 84, 161-7	5.9	65
95	Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. <i>Thrombosis Research</i> , 2013 , 132, 666-70	8.2	52
94	Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1071-7	2.2	45
93	Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 1189-1197	13.4	39
92	Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. <i>British Journal of Cancer</i> , 2010 , 102, 1687-91	8.7	38
91	Inoperable stage III non-small cell lung cancer: Current treatment and role of vinorelbine. <i>Journal of Thoracic Disease</i> , 2011 , 3, 197-204	2.6	38
90	Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2020 , 22, 989-1003	3.6	36
89	First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2011 , 72, 84-91	5.9	35

88	Applications of genomics in NSCLC. <i>Lung Cancer</i> , 2005 , 50, S33-S40	5.9	34
87	Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications. <i>Clinical Lung Cancer</i> , 2015 , 16, 431-46	4.9	33
86	Platinum resistance related to a functional NER pathway. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 1063-6	8.9	32
85	Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). <i>Clinical and Translational Oncology</i> , 2012 , 14, 338-49	3.6	29
84	Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. <i>Annals of Oncology</i> , 2019 , 30, 290-296	10.3	29
83	Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2004 , 6, 175-83	4.9	25
82	Evaluation of the VeriStrat serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. <i>Lung Cancer</i> , 2017 , 109, 101-108	5.9	24
81	Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. <i>Lung Cancer</i> , 2012 , 76, 354-61	5.9	24
80	Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017 , 18, 43-49	4.9	23
79	Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study. <i>Lung Cancer</i> , 2013 , 81, 84-90	5.9	22
78	Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. <i>Clinical and Translational Oncology</i> , 2011 , 13, 460-71	3.6	22
77	Prognostic Value of Serum S-100B in Malignant Melanoma. <i>Tumori</i> , 2004 , 90, 607-610	1.7	22
76	ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p). <i>Journal of Clinical Oncology</i> , 2005 , 23, 7002-7002	2.2	22
75	Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2015 , 17, 103-12	3.6	21
74	MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. <i>Lung Cancer</i> , 2012 , 76, 373-9	5.9	21
73	Genome-wide significant association between a sequence variant at 15q15.2 and lung cancer risk. <i>Cancer Research</i> , 2011 , 71, 1356-61	10.1	21
72	Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. <i>Clinical Breast Cancer</i> , 2005 , 6, 158-62	3	21
71	SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019). <i>Clinical and Translational Oncology</i> , 2020 , 22, 245-255	3.6	20

70	Pharmacogenomics and gemcitabine. <i>Annals of Oncology</i> , 2006 , 17 Suppl 5, v13-16	10.3	20
69	Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2004 , 5, 360-5	4.9	20
68	SEOM Clinical Guideline for bone metastases from solid tumours (2016). <i>Clinical and Translational Oncology</i> , 2016 , 18, 1243-1253	3.6	20
67	Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. <i>Annals of Oncology</i> , 2014 , 25, 2147-2155	10.3	19
66	Lung cancer in women: an overview with special focus on Spanish women. <i>Clinical and Translational Oncology</i> , 2014 , 16, 517-28	3.6	17
65	A consensus statement on the gender perspective in lung cancer. <i>Clinical and Translational Oncology</i> , 2017 , 19, 527-535	3.6	16
64	Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. <i>Lung Cancer</i> , 2019 , 134, 72-78	5.9	15
63	Lung cancer and treatment in elderly patients: the Achilles Study. <i>Lung Cancer</i> , 2009 , 66, 103-6	5.9	15
62	A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. <i>Lung Cancer</i> , 2017 , 108, 154-160	5.9	13
61	Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. <i>ClinicoEconomics and Outcomes Research</i> , 2017 , 9, 31-38	1.7	13
60	SEOM clinical guidelines for diagnosis and treatment of testicular seminoma (2010). <i>Clinical and Translational Oncology</i> , 2011 , 13, 560-4	3.6	12
59	SEOM clinical guidelines for the treatment of thyroid cancer. <i>Clinical and Translational Oncology</i> , 2011 , 13, 574-9	3.6	12
58	SEOM clinical guidelines for hereditary cancer. <i>Clinical and Translational Oncology</i> , 2011 , 13, 580-6	3.6	12
57	SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). <i>Clinical and Translational Oncology</i> , 2009 , 11, 284-9	3.6	12
56	Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008 , 31, 335-9	2.7	12
55	Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance. <i>Npj Precision Oncology</i> , 2020 , 4, 15	9.8	11
54	Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia. <i>Journal of Medical Economics</i> , 2007 , 10, 27-39	2.4	11
53	Zoledronic acid in lung cancer with bone metastases: a review. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 421-6	3.5	10

52	MDR-1 C3435T genetic polymorphism and tobacco-related lung cancer. <i>Oncology</i> , 2003 , 64, 183-5	3.6	10
51	Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. <i>Clinical and Translational Oncology</i> , 2020 , 22, 759-771	3.6	10
50	Reflections on the Implementation of Low-Dose Computed Tomography Screening in Individuals at High Risk of Lung Cancer in Spain. <i>Archivos De Bronconeumologia</i> , 2017 , 53, 568-573	0.7	9
49	SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS). <i>Clinical and Translational Oncology</i> , 2011 , 13, 545-51	3.6	9
48	Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer. <i>Lung Cancer</i> , 2009 , 63, 83-7	5.9	9
47	Case 4. Hypertrophic osteoarthropathy associated with pulmonary metastasis of uterine leiomyosarcoma. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3540-1	2.2	9
46	Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. <i>BMC Cancer</i> , 2018 , 18, 106	4.8	8
45	From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy. <i>Cancers</i> , 2020 , 12,	6.6	8
44	Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection. <i>Lung Cancer</i> , 2021 , 153, 25-34	5.9	8
43	SEOM guidelines for the treatment of malignant pleural mesothelioma. <i>Clinical and Translational Oncology</i> , 2011 , 13, 569-73	3.6	7
42	Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2010 , 68, 491-7	5.9	7
41	Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: results of the NeoPrevent study. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 59, 35-42	3.5	7
40	Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2015 , 17, 11-23	3.6	6
39	Recomendaciones para la determinaci3n de biomarcadores en el carcinoma de pulm3n no microc3nico avanzado. Consenso nacional de la Sociedad Espa3ola de Anatom3a Patol3gica y de la Sociedad Espa3ola de Oncolog3a M3dica. <i>Revista Espanola De Patologia</i> , 2012 , 45, 14-28	1.2	6
38	Functions and workload of medical oncologists in Spain. <i>Clinical and Translational Oncology</i> , 2012 , 14, 423-9	3.6	6
37	Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC). <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 253-61	3.5	6
36	Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07. <i>Anticancer Research</i> , 2016 , 36, 6647-6653	2.3	6
35	Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. <i>Clinical Lung Cancer</i> , 2019 , 20, e407-e412	4.9	6

34	Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07. <i>Cancer Investigation</i> , 2017 , 35, 358-365	2.1	5
33	SEOM clinical guidelines for the treatment of anal cancer. <i>Clinical and Translational Oncology</i> , 2011 , 13, 525-7	3.6	5
32	Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines. <i>Clinical and Translational Oncology</i> , 2011 , 13, 536-44	3.6	5
31	SEOM clinical guidelines for the treatment of invasive bladder cancer. <i>Clinical and Translational Oncology</i> , 2011 , 13, 552-9	3.6	5
30	The place of targeted therapies in the management of non-small cell bronchial carcinoma: Molecular markers as predictors of tumor response and survival in lung cancer. <i>Revue Des Maladies Respiratoires</i> , 2006 , 23, 131-136	0	5
29	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. <i>EClinicalMedicine</i> , 2021 , 37, 100940	11.3	5
28	Intratumoral Versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One?. <i>Cells</i> , 2020 , 9,	7.9	4
27	Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database. <i>Clinical and Translational Oncology</i> , 2017 , 19, 1537-1542	3.6	4
26	SEOM guidelines: non-seminomatous germ cell cancer (NSGCC). <i>Clinical and Translational Oncology</i> , 2011 , 13, 565-8	3.6	4
25	SEOM guidelines on thrombosis in cancer patients. <i>Clinical and Translational Oncology</i> , 2011 , 13, 592-6	3.6	4
24	Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors. <i>Clinical and Translational Oncology</i> , 2009 , 11, 428-36	3.6	4
23	Pharmacogenetics in lung cancer for the lay doctor. <i>Targeted Oncology</i> , 2008 , 3, 161-171	5	4
22	Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapy. <i>British Journal of Cancer</i> , 2002 , 86, 1017-8	8.7	4
21	Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study). <i>Lung Cancer</i> , 2019 , 135, 161-168	5.9	4
20	SEOM clinical guidelines for the treatment of pancreatic cancer. <i>Clinical and Translational Oncology</i> , 2011 , 13, 528-35	3.6	3
19	Early intervention with epoetin beta prevents severe anaemia in lung cancer patients receiving platinum-based chemotherapy: a subgroup analysis of the NeoPrevent study. <i>Lung Cancer</i> , 2008 , 59, 211-8	5.9	3
18	Menstrual status and lung cancer in female patients from the Spanish WORLD07 database.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e12012-e12012	2.2	3
17	Lung cancer in Spanish women: The WORLD07 project. <i>European Journal of Cancer Care</i> , 2019 , 28, e12941.4	1.4	3

16	Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy. <i>Clinical and Translational Oncology</i> , 2017 , 19, 219-226	3.6	2
15	-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy. <i>Lung Cancer: Targets and Therapy</i> , 2017 , 8, 207-216	2.9	2
14	SEOM clinical guidelines for the treatment of oesophageal cancer. <i>Clinical and Translational Oncology</i> , 2011 , 13, 520-4	3.6	2
13	Actualizaci3n de las recomendaciones para la determinaci3n de biomarcadores en el carcinoma de pulm3n avanzado de c3lula no peque1a. Consenso Nacional de la Sociedad Espa1ola de Anatom3a Patol3gica y de la Sociedad Espa1ola de Oncolog3a M3dica. <i>Revista Espanola De Patologia</i> , 2015 , 48, 80-89	1.2	1
12	Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery. <i>Clinical Lung Cancer</i> , 2017 , 18, 178-188.e4	4.9	1
11	Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital. <i>Clinical and Translational Oncology</i> , 2012 , 14, 820-6	3.6	1
10	Never-smoking women with lung cancer from the Spanish WORLD07 database.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1531-1531	2.2	1
9	Population survey to assess the knowledge of smoking habit and its consequences on women (w) in Spain.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e12000-e12000	2.2	1
8	PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
7	Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-10).. <i>Lung Cancer</i> , 2022 , 166, 107-113	5.9	0
6	Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus. <i>Clinical and Translational Oncology</i> , 2021 , 23, 1304-1313	3.6	0
5	Reflections on the Implementation of Low-dose Computed Tomography Screening in Individuals at High Risk of Lung Cancer in Spain. <i>Archivos De Bronconeumologia</i> , 2017 , 53, 568-573	0.7	
4	In answer to: Comments to SEOM clinical guidelines for the treatment of thyroid cancer by Garcilaso Riesco-Eizaguirre et al. <i>Clinical and Translational Oncology</i> , 2012 , 14, 711-712	3.6	
3	SEOM clinical guidelines for using molecular markers in clinical practice. <i>Clinical and Translational Oncology</i> , 2011 , 13, 587-91	3.6	
2	Radiation pneumonitis after local-regional radiotherapy following autologous stem-cell transplant for high-risk breast cancer. <i>Annals of Oncology</i> , 1999 , 10, 1529	10.3	
1	Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study. <i>BMC Psychology</i> , 2020 , 8, 123	2.8	